Navigation Links
Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference

SEATTLE, Sept. 8 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that executives will present a corporate update at the upcoming Morgan Stanley Global Healthcare Conference in New York City. Peter Thompson, M.D., FACP, president, chief executive officer and chairman of the board of directors, and Michelle Burris, senior vice president and chief financial officer, are scheduled to present on Monday, Sept. 14 at 8 a.m. EDT. The presentation will be available via audio webcast at


About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the company's Facet Biotech collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules like CD79b and HLA-DR, as well simultaneously neutralizing soluble ligands like TNF and IL-6. More information is available in the investors section of Trubion's website:


    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals, Inc.
    (206) 838-0500

    Waggener Edstrom Worldwide Healthcare
    Amy Petty
    Senior Account Executive
    (617) 576-5788

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
4. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
5. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
6. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
7. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
10. Trubion Announces Presentations at Upcoming Investor Conferences
11. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... and partnering meetings taking place in the month of ... – Partnering Forum RepliCel will be presenting at ... Meeting on the Mesa to be held October 7-9 ...
(Date:10/8/2015)... ... October 08, 2015 , ... ... an exclusive license agreement to develop and commercialize intellectual property rights belonging to ... agreement from February 2009, and affords exclusive worldwide rights to intellectual property based ...
(Date:10/7/2015)... (PRWEB) , ... October 07, 2015 , ... Neil Riordan, ... Beach Anti-Aging Summit Tomorrow, October 8th, at Mar-a-Lago from 3:50 pm to 4:30 pm. ... adult stem cell therapy. , He is the Co-Founder and Chief Science ...
(Date:10/7/2015)... --  PDI , a leader in infection prevention products ... challenges across various healthcare settings, as well as guidelines ... tool is part of a larger effort to raise ... and lower healthcare-associated infections. ... how to use the right product, in the right ...
Breaking Biology Technology:
... 9, 2011) The brain is a black box. ... much like the inner workings of a computer chip. ... economy of an assembly line, neural circuits are impenetrable ... Department of Neurobiology have developed a technique for unraveling ...
... of Standards and Technology (NIST),have demonstrated an ... mechanical component 1,000 times,more vigorously than ever ... a new tool for processing,information and potentially ... object at the,smallest possible, or quantum, scale. ...
... NEW YORK, March 9, 2011 ... is available in its catalogue: ... and Market Forecasts to 2017 ... Retinopathy Therapeutics - Pipeline Assessment and Market ...
Cached Biology Technology:
(Date:10/7/2015)... , October 8, 2015 ... revenues for Fingerprint Cards (FPC) during third quarter 2015 amounted ... guidance of around 860 MSEK that was communicated 20 August ... a further strengthened delivery capacity and a continued growing demand ... 2015 is estimated to be higher than during the third ...
(Date:10/5/2015)... ) releases the following ... NXTD ), a biometric authentication company focused on the ... ) releases the following market and company update ... authentication company focused on the growing mobile commerce market. ... ) releases the following market and company update ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court of ... another key ruling in favor of Crossmatch ™, ... fingerprint scanner company Suprema and its U.S. partner Mentalix ... a trade provision that declares it unlawful to engage ... infringing two of Crossmatch,s patents, the 5,900,993 patent and ...
Breaking Biology News(10 mins):
... The Proceedings of the National Academy of Science ... Medicine generated a mouse model exhibiting reduced inflammation. ... transcription factor LITAF (Lipopolysaccharide [LPS]-Induced TNF-Alpha Factor) controls ... better known and studied NF-kB transcriptional regulator. ...
... for insects and other small terrestrial animals by firing ... the water's surface. These water shots were once thought ... discovered new levels of sophistication in the archerfish's hunting ... behavior has evolved. The findings are reported by Thomas ...
... at the University of Rochester may have answered one ... our neurons, which are responsible for our crystal-clear thoughts, ... the November issue of Nature Neuroscience, the Rochester study ... "noisy," signals to represent the ambiguities of the real ...
Cached Biology News:
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... imported for data analysis , Automatic grid, subgrid ... template assignment , ... Extensive background and signal options to optimize, ... results , ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
... stocks contained in standard 96-well microtiter plates. ... approximately 5,000 clones per plate. After positive ... the corresponding subplate is screened with a ... well(s). Cells from a positive well are ...
Biology Products: